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Innate  immune  deﬁciencies  are a  heterogeneous  group  of genetically  inherited  diseases  affecting  the
innate  and  adaptive  immune  systems  that  confer  susceptibility  to infection,  autoimmunity,  and  cancer.
This  review  discusses  the  latest  insights  into  the links  between  common  variable  immunodeﬁciency  (CVI)
and malignancies.
Although Ig therapy  greatly  reduces  the  number  of  infections  and  enhances  survival,  it does  not  appeareywords:
ommon variable immunodeﬁciency
ymphoma
astric cancer
mmune dysregulation
nnate immune deﬁciency
to  address  the  development  of cancer,  especially  lymphoma.  The  reasons  for the  increased  susceptibility
to  lymphoid  malignancies  are  unclear.  These  include  genetics,  immune  dysregulation,  radiosensitivity
and  chronic  infections  such  as  Helicobacter  pylori,  EBV,  human  herpes  virus  type 8 and  cytomegalovirus.
Further  studies  will  allow  us to better  stratify  the  risk for cancer  in these  patients,  and  teach  us  to  better
prevent  these  complications  and  to better  treat  them.
©  2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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. Introduction
Usually, researchers divide host defense into two harmonizing
ampliﬁes its response upon re-exposure to the same antigen,
resulting in long-lasting speciﬁc immunity, the innate system is
preformed in the germline. Innate immunity comprises epithelialompartments: innate and adaptive. These work together to efﬁ-
iently prevent, control, and when necessary destroy the broad
ange of pathogens that challenge vertebrates. While T- and B-
ell-mediated adaptive immunity needs DNA rearrangement and
∗ Corresponding author at: Division of Hematology, Department of General
urgery and Oncology, University of Messina, Messina, Italy. Tel.: +39 0902212364;
ax:  +39 0902212355.
E-mail address: aallegra@unime.it (A. Allegra).
1 These authors have equally contributed to the work.
ttp://dx.doi.org/10.1016/j.leukres.2015.02.002
145-2126/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article unand mucosal barriers, natural antimicrobial products, pattern-
recognition receptors, and cytokines.
Innate immune deﬁciencies are a heterogeneous group of genet-
ically inherited diseases affecting the innate and adaptive immune
systems that confer susceptibility to infection, autoimmunity, and
cancer. Although we have an inclination to combine immune deﬁ-
ciencies into subgroups based on cell types or compartments (T
cells, B cells, NK cells, complement, phagocytes), these compart-
ments synergistically interact, creating the complex entity known
as the immune response [1].
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Common variable immunodeﬁciency (CVI) is a clinically signiﬁ-
ant immune defect [2,3]. It is a heterogeneous group of disorders,
haracterized by hypogammaglobulinemia [4], and the incapac-
ty to make speciﬁc antibodies in response to immunization [5].
efects in cellular immunity, which occur in approximately one
hird of patients, likely contribute to their susceptibility to conven-
ional and opportunistic pathogens.
CVI is the most common symptomatic primary antibody disor-
er in adults, with monogenic causes identiﬁed in less than 10% of
ll cases. Although there are no clear-cut data on the prevalence of
VI, prevalence ranging from 1:10,000 to 1:50,000 or 1:100,000, is
stimated [6–8].
Presentation is variable, both in terms of clinical features
nd patient age, although patients usually present with recur-
ent bacterial infections. CVI may  also present with characteristic
on-infective complications. Based on the complications, distinct
linical phenotypes have been proposed.
In an effort to elucidate the association between all disease-
elated complications and prognosis, a large European cohort of
VI patients (with an average follow-up of 25.6 years) was studied
2]. Five phenotypes were deﬁned: infections only, autoimmunity,
olyclonal lymphocytic inﬁltration, enteropathy, and lymphoid
alignancies. Diverse phenotypes were associated with differ-
nt survival times: those subjects without disease complications
infections only) surviving longer than those with autoimmunity
relative risk (RR) of mortality, 2.5), enteropathy (RR, 3.0), poly-
lonal lymphocytic inﬁltration (RR, 4.0) and, not unexpectedly,
ymphoma (RR, 5.5). Polyclonal lymphocytic inﬁltration (in lung,
ymph node, spleen or unexplained granuloma) was associated
ith a 5-fold increased risk of lymphoid malignancy occurring late
n the disease (P = 0.007). High polyclonal IgM levels were found to
orrelate with the development of lymphoma in this series [2].
More recently Cunningham-Rudles pointed out that CVI con-
ists of 2 phenotypes, one in which infections are the characteristic
nd another in which impressive inﬂammatory and/or hema-
ologic complications also develop, including lymphadenopathy,
plenomegaly, autoimmune cytopenias, enteropathy, and/or gran-
lomatous disease. These phenotypes appear to be stable, are
elated to immunologic and inﬂammatory markers, and are pre-
ictive of outcomes [9].
Although Ig therapy greatly reduces the number of bacterial
nfections and likely enhances survival, it does not appear to
ddress the characteristic inﬂammatory complications and the
evelopment of cancer, especially lymphoma.
In fact, a higher frequency of malignancy has been reported in
hese patients [10–16]. The incidence in CVI is around 11–13% and
sually occurs during the ﬁfth or sixth decade of life, with a risk
2–18 times higher than the general population [17]. In 2002, a
ombined study from Denmark and Sweden, using national cancer
nd immunodeﬁciency registries, found a increased incidence of
2-fold [13].
The most common sites of involvement are the gastrointestinal
ract and the lymphoid tissues.
In fact, there is no doubt about the signiﬁcantly higher incidence
f gastric cancer in patients with CVI [18].
. CVI and gastric cancer
Helicobacter pylori infection and pernicious anemia are risk pre-
ictors for gastric cancer in the general population and probably in
atients with CVI. Dhalla et al. performed a review of the literature
or gastric cancer and conducted a cohort study of gastric pathology
n 116 patients with CVI under long-term follow-up. Regardless of
he presence of pernicious anemia or H. pylori infection, patients
ith CVI have an increased risk of gastric cancer and are thereforeFig. 1. Mechanisms of gastric cancer in CVI patients.
a high-risk population [19], and there are some reports of gastric
cancer presenting at a young age in patients with CVI.
The increased risk of gastric cancer in patients with CVI was
recognized in 1985, when a prospective study of 220 patients with
CVI followed for 11 years reported a 47-fold increased risk [20]. In
a different study, patients with CVI also have a 10-fold increased
risk of gastric cancer [13], while in one study, 16% of 120 patients
with CVI in the Immunodeﬁciency Cancer Registry had gastric ade-
nocarcinoma [10]. A multi-center study using Scandinavian cancer
and disease registries reported a SIR of 10.3 (95% CI 2.1–30.2), but
no increased risk in family members of patients with CVI [13]. This
suggests that the increased risk of gastric cancer in CVI relates to the
immunodeﬁciency rather than to genetic traits or H. pylori virulence
shared with relatives.
Nevertheless, outcome studies of large CVI cohorts followed for
medians of 11 and 7 years, respectively, found only four cases of
gastric carcinoma in 472 patients [4,12], indicating that the abso-
lute risk is low (about 1% per decade). A different study [21], showed
an even lower SIR of 6.1 (95% CI 1.26–17.84). While variability in
prevalence from different locations is not surprising, the consider-
able differences, especially over time, suggest that environmental
factors are important [22].
The mechanisms underlying an increased frequency of gastric
cancer in CVI are not understood (Fig. 1). Speciﬁc antibodies (secre-
tory immunoglobulin IgA) have been shown to kill H. pylori in vitro,
and the absence of such antibodies in patients with CVI [23] may
contribute to the risk.
However H. pylori infection does not seem to be more frequent
than in the general population, and although there are no formal
studies, gastric pathology does appear to be more frequent. In 1999
an Italian group studied gastric pathology in a cohort of 65 patients
with CVI after ﬁnding that more than 50% had dyspeptic symptoms.
Upper gastrointestinal endoscopy revealed that 14 of 34 patients
had H. pylori infection, 80% of which was associated with chronic
atrophic gastritis. In this series, two  of 34 had neoplasia (one ade-
nocarcinoma and one high-grade dysplasia), consistent with an
increased risk of gastric cancer in CVI [24].
Furthermore, achlorhydria, which compromise defense against
H. pylori infection in CVI patients, suggests a different cause for
gastric cancer.
De Petris et al. determined the morphological features of CVI-
associated gastric adenocarcinoma (CAGA) and of the background
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astritis. The population of gastric cancer patients with CVI of Mayo
linic in the period 2000–2010 was studied; 6 cases of CVI were
ound in 5793 patients with gastric cancer in the study period. Each
atient underwent gastric resection for which histology slides were
eviewed. Chronic gastritis variables, CVI-related ﬁndings, and fea-
ures of the adenocarcinoma were recorded. CAGA was  of intestinal
ype, with high number of intratumoral lymphocytes (ITLs). Cancer
as diagnosed in younger patients than in the overall popula-
ion of gastric cancer. Severe atrophic metaplastic pangastritis with
xtensive dysplasia was present in the background in 4 cases, with
eatures of lymphocytic gastritis in 2 cases.
Gastric adenocarcinoma at young age with ITLs, accompanied
y atrophic metaplastic pangastritis, should alert the pathologist
f the possibility of CAGA. It follows that, in presence of those char-
cteristics, the search of CVI-associated abnormalities should be
ndertaken in the nonneoplastic tissues [25].
. CVI and lymphoproliferative disorders
Several neoplastic diseases have been reported in CVI patients.
apidly progressive hepatocellular carcinoma in the absence of any
reexisting liver disease has been described [26], while, Van den
rand et al. presented a patient with immunodeﬁciency who  died
f a metastatic angiosarcoma of the liver [27].
However, although the overall incidence of malignancies in CVI
ppears to have increased, the data for cancers other than lym-
homa are difﬁcult to separate out.
Data on Australian patients notiﬁed voluntarily to the Aus-
ralasian Society of Clinical Immunology and Allergy Registry
1990–2008) were linked with national death and cancer reg-
stries. Person-years of follow-up commenced from up to 15 years
efore registration on the CVI Registry or January 1982, the incep-
ion of national cancer registration. Site-speciﬁc, 5-year age-, sex-,
alendar year-, and state-standardized incidence ratios with 95%
onﬁdence intervals (95% CIs) were calculated for all cancers except
onmelanocytic skin cancer. In this study of 416 CVI subjects, there
as a 5-fold increase in cancer overall, but lymphoma/leukemia
as 31.5% of the total [22].
In the US report, performed on 248 consecutively referred CVI
atients of age range 3–79 years who have been followed for a
eriod of 1–25 years, 8.2% of CVI patients had a lymphoid malig-
ancy, all B cell in type. As noted in earlier reports [4,28], lymphoma
as more common in females than males (P 0.04). Of these, non-
odgkin B-cell lymphomas were the most common, with some
f these being further classiﬁed into speciﬁc B-cell phenotypes,
ncluding mucosa-associated lymphoid tissue lymphoma, marginal
one lymphoma, and T cell-rich B-cell EBV-associated lymphoma.
onoclonal B lymphocytosis was also noted.
Lymphomas in CVI are usually extranodal, B cell in type, and,
nlike lymphomas in other congenital immune defects, are more
ommon in subjects in the fourth to seventh decade of life and are
sually EBV negative [28,29]. Cancers of other sorts also developed
n 33 patients (7%) in this study. Other large series have not noted
his high a percentage of lymphoma: 1.6% in Italy, 3% in the ESID
tudy, 3.8% in a previous United Kingdom study, and 2% in a com-
ined Danish/Swedish cohort [12,13,30]. In Danish/Swedish study
uthors examined the risks for cancer among 562 patients with CVI
r IgA deﬁciency and 2071 relatives in 1958–1996. The patients
ere identiﬁed through an Immunodeﬁciency Register and hos-
ital records, while the relatives were traced through population
egisters. Cancer incidence was assessed by linkage to the Cancer
egistries and compared with that in the general population. Lym-
homa, found in 39 cases (8.2%), was the second most common
ause of death in a different cohort [29]. For unclear reasons, this is
 higher overall incidence than other studies [11–13].earch 39 (2015) 389–396 391
Lymphoma as a complication of CVI is present in female patients
with an average of 9 years after diagnosis of CVI; the median age
at diagnosis is 23 years [11,20]. CVI patients may present non-
Hodgkin’s lymphoma generally in 6th and 7th decades and rarely
in pediatric population [7].
Hyperplasia is more frequent than malignant disorders, with
approximately 50% of CVI patients presenting with lymphadeno-
pathy, splenomegaly and/or gastrointestinal nodular lymphoid
hyperplasia.
Petrilli et al. reported a 7-year-old girl affected by CVI who devel-
oped multiple Epstein–Barr virus-associated tumors, represented
by bilateral adrenal smooth muscle tumors (EBV-SMT) and mul-
tifocal diffuse large B-cell lymphoma [31], while Polizzotto et al.
reported a case of Burkitt lymphoma in a CVI patient [32].
MALT lymphomas were frequently reported. A recent review of
extranodal marginal zone lymphomas in CVI patients reports eight
cases of MALT-lymphomas, none of them of gastric location [24,33].
Several other cases of MALT lymphomas, localized in the lung and
salivary glands were published [34–36].
As far other lymphoproliferative disorders, Aghamohammadi
et al. reported 2 siblings with CVI who developed Hodgkin lym-
phoma. However, their father and 1 uncle were also affected by the
same cancer with no immunodeﬁciency state [37].
Recent observations indicate that CVI should be added to the list
of diseases associated with increased numbers of LGLs [38,39].
Finally, a subset of CVI patients with a distinct T-cell
immunophenotype, splenomegaly and granuloma formation has
been described. Jesus et al. reported a patient with CVI with T-
cell lymphoma mimicking juvenile systemic lupus erythematosus
(JSLE). The necropsy showed hepatosplenic T-cell lymphoma with
diffuse involvement of bone marrow, spleen, liver, and lungs. The
lymphoma cells were positive for CD3 immunostaining and nega-
tive for CD20 and lysozyme [40].
Gammon et al. presented 4 cases of CD8(+) Granulomatous cuta-
neous T-cell lymphoma (G-CTCL). Patients presented with papules
and nodules on the trunk and extremities without antecedent patch
or plaque disease. In all cases, biopsy specimens revealed a dense
granulomatous inﬁltrate accompanied by an atypical lymphoid
inﬁltrate of CD8(+) T cells. T-cell clonality studies were positive in
3 of 4 cases. Staging was  negative for nodal involvement, but lung
granulomas were seen in all cases [41].
4. Diagnosis of lymphoma in CVI patients
The lymphomas that arise in patients with immunodeﬁciency or
immune dysregulation differ from those arising in immunocompe-
tent hosts [42].
Lymphadenopathy is very common in CVI and evaluation of
these is not simple; when new nodes appear and persist, biopsy
may  be required. However, lymphomas are more commonly extra-
nodal and appear in unusual locations, and are thus not amenable
to standard follow-up measures. Bone marrow examinations to
look for lymphoma have not been revealing, with the exception
of advanced cases in which the diagnosis was  already established
by other means.
In addition, the underlying alterations of lymphoid tissues
observed in patients with immune disorders have an impact on
the usual criteria for the diagnosis of lymphoma. For example,
extra-nodal lymphomas arising in MALT, produce prominent lym-
phoid inﬁltration of extra-nodal sites that usually lack lymphoid
tissue, such as the lung or the stomach. However, patients with
CVI often exhibit marked lymphoid inﬁltration of a reactive nature
in MALT-associated sites, making the distinction between benign
and malignant lymphoid proliferations ambiguous. Criteria for the
diagnosis of malignancy include demonstration of a monoclonal
392 S. Gangemi et al. / Leukemia Res
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rocess either by immunophenotypic or molecular means and in
ome cases, the acquisition of cytogenetic aberrations.
Higher baseline serum IgM levels were associated with
ncreased risk of lymphoma. In this regard, females with CVI
ad higher levels of serum IgM, and greater numbers of isotype
witched memory B cells, and possibly not coincidentally, a higher
ncidence of B-cell lymphoma [4,28,29,43].
As far the prognosis, serum levels of sCD30 in the patients
ith CVI were signiﬁcantly increased in comparison with con-
rols (36.93 + −32.38 vs 5.27 + −1.32 U/ml, P < 0.001). The group
f patients with splenomegaly and reversed ratio of CD3+CD4+
 cells/CD3+CD8+ T cells had the highest serum levels of
CD30 (66.01 + −43.34 U/ml) in comparison with other patients
P = 0.010). High levels of sCD30 in the CVI patients with
plenomegaly and the presence of lymphoma in a patient with the
ighest level of sCD30 may  suggest a soluble form of this marker
s a prognostic tool in such diseases [44].
. Pathogenesis of lymphoproliferative disease in CVI
atients
The reasons for the increased susceptibility to lymphoid malig-
ancies are unclear.
Patients who have defective immune responses may  be suscep-
ible to malignancies due to complicated underlying mechanisms.
here are several reasons for an increased risk of lymphoma in
VI patients, and these include genetics, immune dysregulation,
adiosensitivity and chronic infections (Fig. 2).
The interaction between chronic infections and the develop-
ent of lymphoma is still unclear but studies to clarify this may
ead to prevention measures and lymphoma reduction strate-
ies [45]. In fact, the observed prevalence of lymphoma may
e due to virus infection or reactivation of weakness of the
mmune system. Furthermore, CVI patients with systemic and local
ranulomatosis are more susceptible to developing lymphoma;
he diseases may  have the same origin, i.e., immune dysregula-
ion and infection with B-cell lymphotropic human herpes virus
ype 8 (HHV8). HHV8 is a -herpes virus that also is known
s Kaposi’s sarcoma (KS)-associated virus [46]. In the context of
econdary immunodeﬁciencies, such as HIV-1 infection or organ
ransplantation, HHV8 is an opportunistic pathogen that is linkedearch 39 (2015) 389–396
to the development of lymphoproliferative diseases (e.g., pri-
mary effusion lymphoma and multicentric Castleman’s disease).
The proclivity of HHV8 to cause lymphoproliferative disorders in
the setting of immunodeﬁciency, together with observations that
CVI-GLILD (granulomatous/lymphocytic interstitial lung disease)
patients were highly susceptible to lymphoproliferative disease,
prompted to determine if HHV8 infection was present in the blood
and affected tissues of patients with CVI and GLILD [47]. Moreover,
levels of inﬂammatory cytokines, such as IL-6 and TNF-, also are
elevated in HHV8-induced malignancies (20). IL-6 enhances the
replication of HHV8 and TNF- and IL-6 may  play an important
role in the promotion of HHV8-induced malignancies [48].
Therefore, it is possible to hypothesize that the lymphoprolifera-
tive disease that is seen in the CVI-GLILD cohort of patients, is due
to the unique interplay of HHV8 infection, cellular and humoral
immunodeﬁciency, and polymorphisms within the promoters of
inﬂammatory cytokine genes (Table 1).
It is possible that other viruses, in addition to HHV8, are involved
in the pathogenesis of lymphoproliferative disorders in CVI [49,50].
EBV is found in a small number of B cell lymphomas in patients
with CVI, including in one patient with an HHV8-negative, primary
effusion lymphoma [51]. Prospective studies that examine larger
numbers of patients need to be performed to determine the role of
these and other transformation-competent viruses in the etiology
of lymphomas that occur in the context of CVI.
Importantly, more than half of the CVI patients has T-cell abnor-
malities including decreased lymphocyte response to mitogens and
microbial antigens [52]. This has been proposed as an explanation
for the increased risk of malignancy, in keeping with the increased
prevalence in other groups with low CD3 numbers such as in HIV
infection. However, low numbers of CD3 cells in CVI patients are
associated with opportunistic infections and not with lymphoid
malignancies, though there are low numbers of such patients in
any series [53].
Approximately, half of the cases have signs of T-cell deﬁcien-
cies contributing to the defective antibody production [4,54]. It’s
demonstrated that CVI patients have decreased numbers of T-
helper-17 (Th17) cells in their circulation [55].
Mutations have been identiﬁed in various B-cell related
inducible T-cell costimulator (ICOS), transmembrane activator and
calcium modulator and cyclophilin ligand interactor (TACI), B-cell
activating factor-receptor (BAFF-R), in members of the CD19-B-cell
receptor (BCR) complex (CD19, CD21 and CD81) and CD20. More-
over, polymorphisms in genes involved in deoxyribonucleic acid
(DNA) repair (MSH5, MSH2, MLH1, RAD50 and NBS1) have also
been reported in patients with CVI [56–63].
Lower total and CD4+ T cells and natural killer cells in terms of
number and function have been strongly associated with risk for
subsequent development of malignancy in CVI patients [45].
A reduction in the number of iNKT cells in patients with CVI
compared with healthy controls was also observed, and a signiﬁ-
cant association was seen between the number of iNKT cells and
the percentage of class-switched memory B cells and propensity to
lymphoproliferation in patients with CVI. iNKT cells are deﬁcient
and/or functionally impaired in most of the patients with CVI [64].
However, the relationship between T and B-cell abnormalities
remains unclear. A subset of CVI patients harbors a polyclonal
expansion of large granular lymphocytes (LGLs) with a distinctive
T-cell immunophenotype characterized by CD4/CD8 ratio < 0.9, in
some cases due to an increase in CD8+ T-cells expressing CD57 [65].
The inherent genetic instability of lymphocytes and sustained
activation and proliferation of the lymphoid system during infec-
tions increases the risk of malignant transformation [66,67]. The
ﬁnding that genes involved in lymphoproliferation are signiﬁcantly
associated with particular subgroups of CVI patients in the recent
genome-wide association, and gene copy number variation study
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Table  1
Studies on increased incidence of lymphoproliferative disease and gastric cancer in CVID patients.
Authors Year of pub. CVID patients Study Ref.
Lymphoprolipherative disease
Hermaszewski et al. 1993 240 Retrospective study [11]
Quinti et al. 2007 224 Multicenter prospective study [12]
Mellenkyear et al. 2002 176 Retrospective study [13]
Cunningham-Rudles et al. 1987 98 Prospective study [29]
Reichenbergher et al. 2001 1 Case report [34]
Cunningham-Rudles et al. (Am J Hematol) 2002 5 Case report [35]
Gastric cancer
Cunningham-Rudles et al. 1999 248 Retrospective study [4]
Gompels et al. 2003 29 Retrospective study [10]
Quinti et al. 2007 224 Multicenter propective study [12]
Mellemkjaer et al. 2002 176 Retrospective study [13]
Dhalla et al. 2011 116 Cohort study [19]
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upports this theory. CVI has been associated recently with a dra-
atic increase in total copy number variation burden, the cause
f which is unclear. However, in order to explore further the origin
nd clinical relevance of this ﬁnding, Keller et al. quantiﬁed the total
enomic copy number variation (CNV) burden in affected patients
nd evaluated clinical details in relationship to total CNV burden.
igher total burden did not correlate with incidence of malignancy.
hese ﬁndings could suggest that the increased CNV burden is static
nd intrinsic to CVI as a disease [68].
In any case, genes were found to be signiﬁcantly associated with
he subsequent development of lymphoma, including PFTK1 that is
onstitutively expressed at high levels in B cell lymphomas. A sig-
iﬁcantly high number of patients were found to have duplications
n a gene for initiation of DNA replication, namely ORC4L, which
s associated with B cell lymphoproliferative disorders. However,
uch studies are in the beginnings and need to be conﬁrmed before
hey can be used as predictors of clinical phenotypes in CVI [69,70].
Newly identiﬁed disease genes within the CVI population,
ave advanced the understanding of human immunodeﬁciency
nd the molecular basis of B-cell biology [71–78]. Five differ-
nt G protein-coupled sphingosine-1-phosphate (S1P) receptors
S1P1-S1P5) regulate a variety of physiologic and pathophysiologic
rocesses, including lymphocyte circulation, and cancer. Although
-lymphocyte circulation plays an important role in these pro-
esses and is essential for normal immune responses, little is known
bout S1P receptors in human B cells.
To explore their function and signaling, Sic et al. studied B-
ell lines and primary B cells from control subjects, patients with
eukemia, patients with S1P receptor inhibitor-treated MS,  and
atients with primary immunodeﬁciencies [79]. Showing that dif-
erent B-cell populations express different combinations of S1P
eceptors, they found that S1P1 promotes migration, whereas S1P4
odulates and S1P2 inhibits S1P1 signals. Expression of CD69 in
ctivated B lymphocytes and B cells from patients with chronic
ymphocytic leukemia inhibited S1P-induced migration. Study-
ng B-cell lines, normal B lymphocytes, and B cells from patients
ith primary immunodeﬁciencies, they identiﬁed Bruton tyro-
ine kinase, -arrestin 2, LPS-responsive beige-like anchor protein,
edicator of cytokinesis 8, and Wiskott–Aldrich syndrome protein
s critical signaling components downstream of S1P1. Thus S1P
eceptor signaling regulates human B-cell circulation and might
e a factor contributing to the pathology of chronic lymphocytic
eukemia, and primary immunodeﬁciencies.
As for other genes, two adult siblings, one with CVI, of a consan-
uineous marriage have been reported that carrying a homozygous
4 bp in-frame deletion in exon 2 of the TNFRSF13C gene [63].
ne sibling (the brother) had decreased IgG and IgM levels but
ormal IgA and the other (the sister), who was  clinically normal,
ad a slightly diminished IgG and IgM levels in her serum. In other985 377 Prospective study [20]
010 1132 Retrospective study [22]
999 34 Prospective study [24]
studies, heterozygous sequence variations in the BAFF-R gene
(CVID4, MIM#613494) have been reported [80,81]. The signiﬁcance
of these mutations on lymphoproliferative disorders is unclear.
6. Immunodeﬁciencies and hematopoietic system
Several other types of immunodeﬁciencies are known. These
diseases do not only predispose to infection but also bear increased
risk of cancer.
A number of independent groups have begun to deﬁne novel
immunodeﬁciences caused by defects in the caspase recruitment
domain family, member 11 (CARD11)-B-cell chronic lymphocytic
leukemia/lymphoma 10 (BCL10)-mucosa-associated lymphoid tis-
sue lymphoma translocation gene 1 (MALT1 [CBM]) signalosome
complex. The CBM complex forms an essential molecular link
between the triggering of cell-surface antigen receptors and
nuclear factor B activation. Germline mutations affecting the CBM
complex are now recognized as the cause of novel combined immu-
nodeﬁciency phenotypes, which all share abnormal nuclear factor
B activation and dysregulated B-cell development as deﬁning fea-
tures [82].
Moreover, inherited defects in Non-homologous-end-joining
(NHEJ)-mediated-DNA double strand breaks (DSBs) repair, account
for ∼15% of human severe combined immunodeﬁciencies [83]. The
ability to repair DSBs is especially important for adult stem cells,
which are responsible for tissue replenishment in long-lived multi-
cellular organisms. This is best exempliﬁed in the hematopoietic
system, which is maintained by small numbers of hematopoietic
stem cells (HSCs) in the bone marrow and which by requirement of
their function must maintain their genomic stability at all costs. As
such, defects in various forms of DNA repair pathways must have
deleterious consequences for these cells. Pluripotent stem cells rely
heavily on error prone NHEJ to repair IR and culture induced DSBs,
which has the potential to lead to genomic instability and cancer
[84–88].
Leukocyte adhesion deﬁciency type 1 (LAD 1 – CD18 deﬁciency)
is a rare disease characterized by disturbance of phagocyte function
associated with less severe cellular and humoral dysfunction.
De Moraes Vasconcelos et al. reported a 20 year-old female pre-
senting a partial CD18 deﬁciency that developed a megakaryocytic
(M7) acute myeloid leukemia. The clinical features of the patient
included relapsing oral thrush due to Candida, cutaneous infec-
tions and upper and lower respiratory tract infections, followed
by a locally severe necrotic genital herpetic lesion. The patient’s
clinical features improved for a period of approximately two years,
followed by severe bacterial infections. At that time, the investi-
gation showed a megakaryocytic acute myeloid leukemia, treated
without clinical improvement [89].
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In a different study, Emir et al. evaluated children with pri-
ary immunodeﬁciency that developed NHL. Two patients had
taxia-telangiectasia, one patient had Bloom’s Syndrome, and one
atient had Wiskott–Aldrich syndrome. Patients had B- and T-cell
ymphoma [90].
Dedicator of cytokinesis 8 (DOCK8) is a member of the DOCK180
uperfamily of guanine nucleotide exchange factors, which interact
ith Rho GTPases. Autosomal recessive DOCK8 deﬁciency is asso-
iated with a novel variant of combined immunodeﬁciency [91].
hang et al. described 11 patients who had a combined immu-
odeﬁciency with low numbers of T, B, and natural killer cells,
xtensive cutaneous viral infections, and susceptibility to cancer.
hese patients had loss-of-function mutations in the gene DOCK8,
hich is expressed in lymphocytes [92].
Besides lymphopenia, DOCK8 deﬁciency has several manifes-
ations including cancers related to cutaneous viral infections.
quamous-cell cancers occurred in three of patients who had
xtensive human papillomavirus infections, and one patient also
ad cutaneous T-cell lymphoma–leukemia. Impaired CD8 T cells
n DOCK8 deﬁciency suggests that these cancers may be due to
mpaired tumor surveillance. It is also possible that DOCK8 has
umor-suppressor functions. Indeed, DOCK8 deletions in primary
ung cancers, gastric- and breast-cancer lines, and gliomas suggest
 role of DOCK8 in tumor suppression [93,94].
Varan et al., evaluated patients with different immunodeﬁ-
iency syndromes who had developed malignant solid tumors
nd examined survival rates and prognosis with respect to
ype of immunodeﬁciency disease. Twenty-two patients who
ere diagnosed with malignant solid tumors and immunodeﬁ-
iency syndromes between January 1972 and February 2003 were
nalyzed retrospectively. There were 12 (55%) patients with non-
odgkin lymphoma, 8 (37%) with Hodgkin disease, 1 (5%) with
ucinous adenocarcinoma of the colon, and 1 (5%) with brain stem
lioma. Fifteen (68%) patients had ataxia-telangiectasia, 3 (14%) had
ommon variable immunodeﬁciency disease, 2 (9%) had Bloom syn-
rome, 1 (5%) had combined immunodeﬁciency, and 1 (5%) had
elective immunoglobulin A deﬁciency. Out of the 15 patients with
taxia-telangiectasia 9 patients had non-Hodgkin lymphoma, 5 had
odgkin disease, and 1 had brain stem glioma. One of the patients
ith Bloom syndrome had Hodgkin disease and 1 had colon car-
inoma. The overall survival for the whole group was  24%. Overall
urvival rates in non-Hodgkin lymphoma, Hodgkin disease, colon
arcinoma, and brain stem glioma were 17, 44, 0, and 0% (P = 0.25),
espectively. Overall survival in ataxia-telangiectasia patients was
0%. In this series, most of the patients had ataxia-telangiectasia
68%). The survival rates of the malignant diseases were very poor
n immunodeﬁciency. Overall survival in non-Hodgkin lymphoma
atients was relatively worse than Hodgkin disease patients [95].
. Conclusion
The treatment of CVI involves infusion of replacement doses
f immunoglobulin, either intravenously or subcutaneously. How-
ver, it is unclear whether adequate replacement of immunoglob-
lins is sufﬁcient to prevent the increased risk of malignancy seen
n this disease [96].
In fact, although the survival of subjects with CVI has improved
arkedly over time, it does not compare to age-matched subjects
f the same sex. For the US study, 58% of female patients with CVI
urvived more than 4 decades, compared with 80% of age-matched
emale subjects; 53% of males survived compared with 68% of age-
atched male subjects. Due to the heterogeneity of the population
ollowed over this period, the median age at death was  44 years
range, 10–90) for female subjects and 42 years (range, 9–79) for
ale subjects: not signiﬁcantly different. The predominant causesearch 39 (2015) 389–396
of death included respiratory failure from chronic lung disease,
lymphoid or other malignancies, or overwhelming infections [15].
Not all complications appeared to be associated with
reduced survival. Patients with gastrointestinal disease (HR = 2.78;
P = .0004), liver disease/hepatitis (HR = 2.48; P = .0003), lymphoma
(HR = 2.44; P = .001), chronic lung disease leading to functional lung
disease (HR = 2.06; P = .001), or malabsorption (HR = 2.06; P = .022)
had reduced survival in this interval compared with CVI patients
without these particular complications. In contrast, patients with
any of the autoimmune conditions, cancers other than lymphoma,
history of splenectomy, presence of granulomatous disease, or the
development of bronchiectasis alone, did not have signiﬁcantly
reduced survival over the 4 decades of study.
One of the questions that have arisen is how to follow CVI sub-
jects over time. Due to the heterogeneity of this disease, there are
no set rules aside from therapy, regularly scheduled follow-ups,
and periodic monitoring of serum Ig levels.
Management of these patients remains problematic. There is a
great need to develop new therapeutic approaches in this group.
The use of rituximab in combination with CHOP may  provide a
promising treatment option for B-cell lymphomas associated with
immunodeﬁciency.
Children with primary immunodeﬁciency cannot tolerate
standard chemotherapy regimens. Shabbat et al. reported two
children with diffuse, large B-cell lymphoma; one had ataxia
telangiectasia and one had common variable immunodeﬁciency.
Both were given rituximab, one as monotherapy and one in com-
bination with a reduced CHOP regimen. Complete remission was
obtained in each patient. Use of rituximab as a ﬁrst-line monother-
apy or in conjunction with reduced chemotherapy should be
considered to reduce cytotoxic effects [97].
The ﬁeld of study on the relationship between immunodeﬁ-
ciency and neoplasms is constantly expanding. Continually are
being reported connections with other neoplastic hematologic and
or solid, and new possible causal links. For instance, the association
between chronic myeloid leukemia (CML) and common variable
immunodeﬁciency is unusual, but there are cases of CVI patients
with CML  [98].
Moreover, it is possible that the immune impairment in CVI
may  have a role in the development of breast cancer by increasing
susceptibility to infection with the mouse-mammary-tumor-virus-
env-gene-like 660 base pair sequence, which has been found in 38%
of human breast cancers [99]. Further studies will allow us to better
stratify the risk for cancer in these patients, and teach us to better
prevent these complications and to better treat them.
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